PPCB Stock Analysis: Buy, Sell, or Hold?
PPCB - Propanc Biopharma, Inc. Common Stock
$2.23
1.16 (108.41%)
▲
5d:
+102.73%
30d:
+125.25%
90d:
+31.18%
WAIT
LOW Confidence
Analysis Updated: Aug 27, 2026 12:00 AM ET
Earnings: Oct 05, 2026
Get Alerted When PPCB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: PPCB is 52.7% above its trading range ($1.46). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: PPCB is 52.7% above its trading range ($1.46). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: PPCB is currently trading at $2.23, which is considered extended relative to its 30-day fair value range of $1.00 to $1.46.
Technical Outlook: Technically, PPCB is in a uptrend. Immediate support is located at $1.05, while resistance sits at $4.13. The stock is showing strong short-term momentum, up 108.4% recently.
Market Sentiment: PPCB scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $1.52 (+42.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PPCB is in a uptrend. Immediate support is located at $1.05, while resistance sits at $4.13. The stock is showing strong short-term momentum, up 108.4% recently.
Market Sentiment: PPCB scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $1.52 (+42.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.00 -
$1.46
Company Quality Score
36/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
15.8%
All Signals
- BEARISH: Price significantly overextended (+52.7% above its trading range)
- BEARISH: Weak technical setup (5/100)
- BULLISH: Strong upward momentum (+108.4%)
- BULLISH: Trading 42.1% below Wall St target ($1.52)
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.00 -
$1.46
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.05
Resistance Level
$4.13
Current Trend
Uptrend
Technical data as of
Aug 27, 2026
Fundamental Context
Wall Street Target
$1.52
(+42.1%)
Share & Embed Analysis
Last updated: August 27, 2026 9:17 PM ET
Data refreshes hourly during market hours. Next update: 10:17 PM
Data refreshes hourly during market hours. Next update: 10:17 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PPCB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 57 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 49 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 45 HOLD |
|
EYPT
EyePoint, Inc |
STRONG BUY
13 analysts |
$27 | 47 HOLD |